Development asset linked to Fresenius Kabi Australia in public FDA and regional records. Mechanism: Peroxisome proliferator-activated receptor gamma agonist.
- Mechanism
- Peroxisome proliferator-activated receptor gamma agonist
pharma · Hypovolemia · Pruritus, Chronic Kidney Diseases
Fresenius Kabi Australia
Fresenius Kabi Australia Pty Limited
Fresenius Kabi Australia drug portfolio — 6 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Mount Kuring-Gai, AU HQ
150 Employees
TGA registrant Type
Company details
- Status
- Public
- HQ
- Mount Kuring-Gai, AU
- Employees
- 150
- Programs
- 5
- Drugs
- 6
- Patents
- 0
Fresenius Kabi Australia pipeline
Portfolio lens on 6 drugs and development assets — regulatory status, targets, and deep links to NovaPharmaNews drug profiles.
Fresenius Kabi Australia drug portfolio — 6 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Drug portfolio
-
-
difelikefalin
Various (V03)Various (V03) compound in Fresenius Kabi Australia's portfolio. Molecular target: Kappa-type opioid receptor.
- Target
- Kappa-type opioid receptor
- Mechanism
- Kappa opioid receptor agonist
-
Development asset linked to Fresenius Kabi Australia in public FDA and regional records.
-
Development asset linked to Fresenius Kabi Australia in public FDA and regional records.
-
Development asset linked to Fresenius Kabi Australia in public FDA and regional records.
-
Development asset linked to Fresenius Kabi Australia in public FDA and regional records.